Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11175357 | 0.97 | SMN1; SMN2 (0.31) | SLC6A3 | |
| SCHEMBL1785405 | 0.95 | — | — | |
| SCHEMBL9886141 | 0.83 | SLC6A3 (0.34) | SLC6A3 | |
| SCHEMBL14141482 | 0.80 | ALDH1A1 (0.35) | SLC6A3 | |
| SCHEMBL757738 | 0.79 | POLB (0.35) | SLC6A3 | |
| SCHEMBL10592697 | 0.79 | POLB (0.33) | — | |
| SCHEMBL8041732 | 0.77 | SLC6A3 (0.31) | SLC6A3 | |
| SCHEMBL22053498 | 0.77 | — | — | |
| SCHEMBL765594 | 0.74 | — | — | |
| SCHEMBL6373685 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046147-B1 | METHOD OF USING ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2013-05-01 | — | — | EP | claimed |
| CN-101494999-A | Method for using organic compound | GIVAUDAN SA (CH) | 2009-07-29 | — | — | CN | claimed |
| US-4240983-A | HALOGENATION | BAYER AKTIENGESELLSCHAFT (DE) | 1980-12-23 | — | — | US | claimed |
| US-20230312455-A1 | PREPARATION OF SUBSTITUTED ACRYLATE COMPOUND | HUA MEDICINE (SHANGHAI) LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| CN-109843087-B | Cognitive function improving composition comprising kaempferol compounds of novel post-fermented tea origin | 株式会社爱茉莉太平洋 | 2023-05-12 | — | — | CN | disclosed |
| CN-109863159-B | Novel kaempferol compound derived from post-fermented tea | 株式会社爱茉莉太平洋 | 2023-04-04 | — | — | CN | disclosed |
| US-8632792-B2 | Cooling sensation agent composition and sensory stimulation agent composition | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2014-01-21 | — | — | US | disclosed |
| US-20110117147-A1 | COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-05-19 | — | — | US | disclosed |
| WO-2011058766-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2011-05-19 | — | — | WO | disclosed |
| WO-2009123355-A2 | COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-10-08 | — | — | WO | disclosed |
| CN-101494999-A | Method for using organic compound | GIVAUDAN SA (CH) | 2009-07-29 | — | — | CN | disclosed |
| US-4240983-A | HALOGENATION | BAYER AKTIENGESELLSCHAFT (DE) | 1980-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117147-A1 | COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION | TRPA1, HRH1, HRH2 | SLC6A3 4853/4885 |
| US-20230312455-A1 | PREPARATION OF SUBSTITUTED ACRYLATE COMPOUND | ACR, ADCYAP1R1, GNPAT | SLC6A3 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.